Foreign patent protection

For many years, the method of obtaining foreign patent protection corresponding to a U.S. patent appHcation was to file separate, individual patent apphcations in selected foreign countries. Each of the appHcations had to be written to conform with the national requirements of the country in which it was filed. 

In most situations the industrial sponsor should try to agree to publication of Background and University Technical Information (subject to prior review by both parties). To circumvent the "academic freedom" obstacle (and protect valuable research developments), corporate sponsors of university research should request the right to review papers or articles by university scientific personnel pertaining to the Sponsored Research field sufficiently in advance of the time they are to be submitted for publication. The advance review period should afford the corporate party adequate time to evaluate the proposed publication for the presence of patentable subject matter or Corporate Technical Information. Publication of an invention prior to filing a patent application can bar most foreign patent protection (e.g. European Patent Convention Article 54) and disclosure. 

Patent medicine industry, 78 683 Patent office gazettes, printed, 78 210-211 Patent portfolio auditing, 78 185 compiling, 78 157 Patent protection, foreign, 78 191 Patent research, in fine chemical research and development, 77 425-426 Patents, 5 766 78 157-197. See also Foreign patents Invention Patentability Trade secrets article of manufacture category in, 78 166... 

Perhaps its author is trying to tell us something about the rate of change in trade secret law by publishing this treatise in loose-leaf form with yearly supplements. A U.S. patent has a fixed term of 17 years and extends protection to the United States only—although its disclosures are worldwide. Foreign patents can be obtained separately in each country and may be quite costly. The scope of protection and subject matter which is patentable varies tremendously. There is action towards patents common to several countries, but the cost is apt to remain high, and many years will be required to determine their effectiveness. 

Those Members that did not provide patent protection for pharmaceutical products when the wto was bom were allowed until 1 January 2005 to implement it. However, under Article 70.8 of trips, these countries still had to establish a mailbox for filing foreign patent applications that would preserve the priority dates of any pharmaceutical... 

Kondo, Edson K (1995). The Effect of Patent Protection on Foreign Direct Investment. Journal of World Trade, 29 97—122. 

Several options are available to applicants at this time. The first is to obtain a patent only in their home country and not pursue patent protection elsewhere. The second possibility is to proceed with a foreign filing in one or more foreign countries within the convention year. A final option is to abandon the home country application and not pursue patent protection. 

The Pharmaceutical Manufacturers Association (PMA) collects sales data of its member firms in an annual survey. U.S.-owned PMA member firms reported that the ratio of total worldwide sales to domestic sales was 1.765 to 1 in 1990 (317). These companies are likely to have a lower percent of sales outside the United States than are foreign-owned firms that launch new products in the United States, and the ratio is based on drugs that have lost patent protection as well as those that are covered by patents. Thus, this ratio is too conservative. 

Protective patents on several of the present major insecticides, fungicides, and herbicides will expire during the 1970 s. Since these products will become commodities, it can be assumed that some domestic as well as foreign producers, who have a good raw material and manufacturing position, will offer them in an already-established domestic market. This situation could give rise to a weakening of prices and a subsequent strain on profits. Also, it could have some influence on the development and introduction of new patent protected chemicals. 

However, an invention must be patented under the United States Patent Act to obtain patent protection in the United States. The United States Patent Act prohibits premature applications for foreign patents for inventions made in the United States. An invention made in the United States cannot be patented here if, before a United States patent is granted, the inventor received a foreign patent on the basis of a patent application filed more than twelve months before the filing of an application for a United States patent. 35 U.S.C. 102(d). If an application for a foreign patent on an invention made in the United States is filed less than six months after an application for a United States patent is filed (except when a license from the Commissioner of Patent and Trademarks allows the foreign filing), any patent issued by the U.S. Patent and Trademark Office is invalid. 35 U.S.C. 184, 185. 

The patentee should develop and implement a poHcy for auditing its patent portfoHo in the process of paying maintenance fees to the U.S. PTO. This practice should also be used to justify the further payment of aimuities to foreign national patent offices. Maintenance fees and aimuities can constitute a substantial portion of funds expended in the protection of patents over a year s time. Further, without a tangible, real commercial value or advantage stemming from the patent, there may be Htde justification for maintaining the patent over its last five years of life. 

Authority for protection of patents and copyrights is set out in the Constitution and is the exclusive province of the federal government. Eederal legislation to protect trademarks is based on the authority of Congress, under the commerce clause of the Constitution, to regulate interstate and foreign commerce of the United States protection afforded by individual states is based on their power to regulate intrastate commerce. 

---